Distribution of PCV13 Pneumococcal Serotypes in Patients With Community-Acquired Pneumonia Presenting at 20 United States Hospitals
Year: 2015
Type: article
Study design: Observational Study
Abstract: Background. In September 2014, PCV13 was recommended by the Advisory Committee on Immunization Practices (ACIP) for all adults ≥65 years old to prevent pneumococcal pneumonia. Since the incidence of PCV13 pneumococcal serotypes in adults with Community-Acquired Pneumonia (CAP) is not well defined, the number of cases that the vaccine may prevent is undefined. The objective of this study was to estimate the incidence and distribution of PCV13 pneumococcal serotypes in US adults presenting to a study hospital with CAP. Methods. This is an ongoing prospective, multicenter, study inclusive of 20 US hospitals. Interim data are presented from 7 October 2013 to 31 October 2014. Eligible patients included adults ≥18 years old with radiographically confirmed CAP. Patients with pneumococcal vaccination within prior 30 days were excluded from the analysis. S. pneumoniae was detected via blood cultures, Binax-NOW urine assay (which detects a polysaccharide common to all pneumococcal serotypes) and a serotype-specific urinary antigen detection (UAD) assay which identifies PCV13 serotypes. Respiratory cultures were recorded if standard of care. Results. A total of 2674 eligible adults were included in the analysis. Median age 64 years, 1299 (49%) were ≥65 years and 1410 (53%) were females. Most prevalent risk conditions were COPD (38%) and current smoker (28%). S. pneumoniae was detected in 378 (14%) patients by any method with 226 (8.5 %) detected by UAD (see figure). PCV 13 serotypes were present in 228 (8.5%) patients; serotype 5 was the most common (see table). Two different serotypes were simultaneously detected in 39 patients. PCV 13 Serotypes From Culture or UAD Figure. Distribution of positive tests for S. pneumoniae by any assay (N = 378). Conclusion. PCV13 serotypes were detected in 8.5% of patients with CAP. These results indicate a persistent burden of adult pneumonia caused by vaccine serotypes, and the appropriateness of current ACIP recommendations. Disclosures. R. Alexander, Pfizer: Employee, Salary; K. Ford, Pfizer: Employee, Salary; S. Gray, Pfizer: Employee and Shareholder, Salary; M. Pride, Pfizer: Employee, Salary; S. Sebastian, Pfizer: Employee, Salary; Q. Jiang, Pfizer: Employee, Salary; R. Isturiz, Pfizer: Employee and Shareholder, Salary
Source: Open Forum Infectious Diseases
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,053
OpenAlex ID: W2275649945